stella
Kidney CancerOctober 2019Summary reviewed September 2026

Kidney Cancer Pill Kept Disease Stable for 9 Months After Immunotherapy Stopped Working

Patients whose metastatic kidney cancer got worse after immunotherapy took axitinib, a pill adjusted to their tolerance. Half stayed stable or improved for nearly 9 months. This was a mid-stage study testing whether personalized dosing works after immunotherapy fails.

What the trial was testing

The trial enrolled 40 patients with kidney cancer. The study was sponsored by Case Comprehensive Cancer Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Half of patients stayed stable or improved for 9 months on this personalized treatment approach.

The Lancet. Oncology · 2019 · NCT02579811

These findings — that half of patients kept their kidney cancer from getting worse for at least 9 months — were published in the The Lancet. Oncology and represent the headline result of the study.

Researchers tracked outcomes across 40 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with kidney cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

If your kidney cancer got worse after immunotherapy, this pill might help. Doctors adjusted the dose based on side effects like fatigue and high blood pressure. This was a mid-stage study and the pill is FDA-approved for kidney cancer, so talk to your oncologist about whether it's right for you after immunotherapy.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.